Raju Sarwal, MD
Ophthalmology · Brentwood, NYNPI 1174627277
Payments from drug & device makers
Across 1,287 payments — averaging $169.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$131K
- Glaukos Corporation$26K
- NEW World Medical,inc.$20K
- Aerie Pharmaceuticals, Inc.$19K
- Alcon$13K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- plus $7K from 24 others
Across 3 payments — averaging $9333.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$28K
What the payments were for
- Consulting fees$5,2753%
- Speaking & faculty fees$152,01578%
- Travel & lodging$3,0212%
- Food & beverage$34,71218%
- Education$180%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 519 | $130,816 |
| Glaukos Corporation | 37 | $25,954 |
| NEW World Medical,inc. | 64 | $19,582 |
| Aerie Pharmaceuticals, Inc. | 35 | $18,694 |
| Alcon | 237 | $12,976 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 35 | $3,164 |
| Oyster Point Pharma, Inc. | 101 | $1,738 |
| Bausch & Lomb Americas Inc. | 67 | $1,274 |
| Sun Pharmaceutical Industries Inc. | 73 | $982 |
| Novartis | 39 | $622 |
| Sight Sciences, Inc. | 9 | $513 |
| Shire North American Group Inc | 21 | $387 |
| Biotissue Holdings Inc. | 11 | $335 |
| Ocular Therapeutix, Inc. | 8 | $225 |
| Ivantis, Inc | 3 | $153 |
| Rxsight Inc | 2 | $152 |
| Kala Pharmaceuticals, Inc. | 6 | $104 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $97 |
| Halozyme Inc | 3 | $62 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Harrow Eye, LLC | 2 | $36 |
| Amgen | 2 | $35 |
| Astellas Pharma US Inc | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Tarsus Pharmaceuticals, Inc. | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| Thea Pharma Inc. | 1 | $19 |
| Dompe US, Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Omeros Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$90,294
- LUMIGAN$25,798
- Rocklatan$18,669
- Rhopressa$13,896
- Ahmed Glaucoma Valve$13,176
- Kahook Dual Blade$13,176
- Clearpath$12,202
- Streamline$12,202
- COMBIGAN$10,034
- Hydrus Microstent$6,359
- ALPHAGAN P$5,987
- Via360$5,280
- VYZULTA$2,600
- iStent Trabecular Micro-Bypass Stent System$2,000
- iStent inject Trabecular Micro-Bypass Stent System$2,000
- Clareon$1,533
- Streamline Surgical System$619
- VUITY$550
- OMNI(R) SURGICAL SYSTEM (US)$386
- iDoseTR$367
How this compares
$218,120 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 726 | $419,135 |
| RestasisCyclosporine | 204 | $285,609 |
| XiidraLifitegrast | 163 | $191,642 |
| CombiganBrimonidine Tartrate/Timolol | 295 | $128,812 |
| RhopressaNetarsudil Mesylate | 169 | $122,228 |
| Cyclosporine | 109 | $80,180 |
| Alphagan PBrimonidine Tartrate | 175 | $67,878 |
| Brimonidine Tartrate | 721 | $44,067 |
| VyzultaLatanoprostene Bunod | 68 | $42,264 |
| Brinzolamide | 137 | $38,366 |
| Travoprost | 130 | $35,951 |
| TyrvayaVarenicline Tartrate | 53 | $33,584 |
| Prednisolone Acetate | 843 | $33,244 |
| CequaCyclosporine | 37 | $32,818 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 188 | $29,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $130,816 | $901,4341,400 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,274 | $233,906231 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $18,694 | $142,043192 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,738 | $33,58453 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $982 | $32,81837 claims |
| AlconSimbrinza, Azopt | $12,976 | $30,94496 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Brentwood
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.